Status: Not yet recruiting
A Study of NST-628 in Recurrent Grade 4 Glioma
This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression who are scheduled for surgical resection. This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability, and anti-tumor activity of NST-628.
Participants needed: 12
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nader SanaiUpdated: Sep 15, 2026Locations: 1
Eligibility criteria
1. Diagnosed with Grade 4 glioma, who have progressed on or following standard o... [+12]
1. Has extracranial disease, or evidence of leptomeningeal disease. [+10]